Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Survival benefit with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis — Davide Mauri (2006) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Survival benefit with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
Shared by
John P A Ioannidis
Stanford University
Survival benefit with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
Article
2006
en
Authors
+2 more
DM
Davide Mauri
NP
Nikolaos P. Polyzos
John P A Ioannidis
Stanford University
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2006
Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis
Davide Mauri
,
Nicholas Pavlidis
,
Nikolaos P. Polyzos
,
John P A Ioannidis
Article
2007
Response: Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis
John P A Ioannidis
,
Davide Mauri
,
Nikolaos P. Polyzos
,
Nicholas Pavlidis
Article
2015
Aromatase inhibitors in male breast cancer: a pooled analysis
Flora Zagouri
,
Theodoros Ν. Sergentanis
,
Hatem A. Azim
,
Dimosthenis Chrysikos
,
Meletios A Dimopoulos
,
Θεοδώρα Ψαλτοπούλου
Article
2005
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Davide Mauri
,
N. Pavlidis
,
John P A Ioannidis
Article
2019
Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival
Maria-Eleni Spei
,
Evangelia Samoli
,
Francesca Bravi
,
Carlo La Vecchia
,
Christina Bamia
,
Vassiliki Benetou
Discussion(0)
No comments yet. Be the first to comment.